RIVASTIGMINE EG LABO 4.6 mg/24 h, patch transdermal 30 sachets
Active ingredients: Rivastigmine
Commercialized according to BDPMDispensing in France: Prescription only
Patch30 sachetstransdermique
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- RIVASTIGMINE EG LABO 4,6 mg/24 h, patch transdermique
- Pharmaceutical form
- patch
- Route of administration
- transdermique
- Presentation description
- 30 sachet(s) papier polytéréphtalate (PET) aluminium polyacrylonitrile avec fermeture de sécurité enfant de 1 patch transdermique
- Marketing authorisation holder
- EG LABO - LABORATOIRES EUROGENERICS
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 2 May 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Initial prescription by a specialist
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
63140325CIP73024297CIP133400930242971Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| RIVASTIGMINEpatch | 6,9 mg · un patch transdermique de 4,6 cm² | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.